Firazorexton
Firazorexton (; development code TAK-994) is an experimental orexin 2 (OX2) receptor agonist first described in a 2019 patent filed by Takeda Pharmaceutical Company. Firazorexton was studied by Takeda for the treatment of narcolepsy. It is a small-molecule and orally active compound and acts as a highly selective agonist of the orexin receptor 2 (OX2) with >700-fold selectivity over the orexin receptor 1 (OX1). Firazorexton is related to danavorexton (TAK-925). The compound reached phase 2 clinical trials for narcolepsy. However, clinical development was discontinued in October 2021 for safety Safety is the state of being protected from harm or other danger. Safety can also refer to the control of recognized hazards in order to achieve an acceptable level of risk. Meanings The word 'safety' entered the English language in the 1 ... reasons. See also * Orexin receptor § Agonists * List of investigational sleep drugs § Orexin receptor agonists References { ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]